Three Fibrotic Conditions Treated with 5% Topical Imiquimod Cream as an Antifibrotic Agent / 대한피부과학회지
Korean Journal of Dermatology
;
: 265-269, 2019.
Artículo
en Coreano
| WPRIM
| ID: wpr-759729
ABSTRACT
Imiquimod, a toll-like receptor agonist, is a topical immunomodulator that induces the production of several cytokines including interferon-alpha, which shows antifibrotic properties. We hypothesized that the antifibrotic effect of imiquimod would soften fibrotic skin lesions. Therefore, we applied topical imiquimod with topical tacrolimus or systemic acitretin in patients with refractory lesions of myxedema, angiolymphoid hyperplasia, and generalized discoid lupus erythematosus and confirmed improvement in fibrotic lesions in these patients. Thus, we conclude that use of imiquimod improves fibrotic skin lesions. This report describes our experience with the treatment of this condition along with a review of the related literature.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piel
/
Fibrosis
/
Lupus Eritematoso Discoide
/
Citocinas
/
Interferón-alfa
/
Tacrolimus
/
Acitretina
/
Receptores Toll-Like
/
Hiperplasia
/
Hiperplasia Angiolinfoide con Eosinofilia
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS